->Rlink2 Bot archive link repair, may include: archive.* -> archive.today, https for ghostarchive.org and archive.org |
refined content and improved wording per standard format |
||
| Line 1: | Line 1: | ||
{{ | {{Use dmy dates|date=December 2022}} | ||
{{Use Indian English|date=December 2022}} | |||
{{ | |||
}} | |||
{{Infobox person | {{Infobox person | ||
| name = Sudhir Srivastava | | name = Sudhir Srivastava | ||
| Line 10: | Line 7: | ||
| caption = | | caption = | ||
| birth_name = | | birth_name = | ||
| birth_date = | | birth_date = | ||
| birth_place = | | birth_place = | ||
| death_date = <!-- {{Death date and age|YYYY|MM|DD|YYYY|MM|DD}} or {{Death-date and age|Month DD, YYYY|Month DD, YYYY}} (death date then birth date) --> | | death_date = <!-- {{Death date and age|df=yes|YYYY|MM|DD|YYYY|MM|DD}} or {{Death-date and age|Month DD, YYYY|Month DD, YYYY}} (death date then birth date) --> | ||
| death_place = | | death_place = | ||
| nationality = | | nationality = | ||
| other_names = | | other_names = | ||
| occupation = [[Scientist]] | | occupation = [[Scientist]] | ||
| Line 21: | Line 18: | ||
'''Sudhir Srivastava''' is chief of the Cancer Biomarkers Research Group of the Division of Cancer Prevention at the United States [[National Cancer Institute|NCI]].<ref name=DCP>{{cite web|url=http://dcp.cancer.gov/about/staff/srivastava-sudhir|title=Division of Cancer Prevention Staff: Sudhir Srivastava|url-status=dead|archiveurl=https://archive.today/20130626171858/http://dcp.cancer.gov/about/staff/srivastava-sudhir|archivedate=2013-06-26}}</ref><ref>{{cite web|url=http://prevention.cancer.gov/about/staff/cb|title=Cancer Biomarkers Research Group|url-status=dead|archiveurl=https://web.archive.org/web/20121008101346/http://prevention.cancer.gov/about/staff/cb|archivedate=2012-10-08}}</ref> Srivastava has held this position since 2000. He is a co-author of the Bethesda Guidelines for the diagnosis of [[Hereditary non-polyposis colorectal cancer]] (HNPCC).<ref name=DCP/> | '''Sudhir Srivastava''' is chief of the Cancer Biomarkers Research Group of the Division of Cancer Prevention at the United States [[National Cancer Institute|NCI]].<ref name=DCP>{{cite web|url=http://dcp.cancer.gov/about/staff/srivastava-sudhir|title=Division of Cancer Prevention Staff: Sudhir Srivastava|url-status=dead|archiveurl=https://archive.today/20130626171858/http://dcp.cancer.gov/about/staff/srivastava-sudhir|archivedate=2013-06-26}}</ref><ref>{{cite web|url=http://prevention.cancer.gov/about/staff/cb|title=Cancer Biomarkers Research Group|url-status=dead|archiveurl=https://web.archive.org/web/20121008101346/http://prevention.cancer.gov/about/staff/cb|archivedate=2012-10-08}}</ref> Srivastava has held this position since 2000. He is a co-author of the Bethesda Guidelines for the diagnosis of [[Hereditary non-polyposis colorectal cancer]] (HNPCC).<ref name=DCP/> | ||
Srivastava is an elected member of the [[American Joint Committee on Cancer]] (AJCC), responsible for developing cancer staging criteria, and serves on the AJCC Executive Committee and the All Ireland-NCI Consortium.<ref>{{cite web|url=http://www.allirelandnci.com/Results.aspx|title=All Ireland-NCI Consortium}}</ref> Srivastava is a founding member of [[HUPO]], participated in the Plasma Proteome and the Liver Proteome Projects, and supported several HUPO-supported initiatives.<ref>{{cite web|url=http://www.hupo.org/research/psi/people.asp|title=HUPO-supported initiatives|url-status=dead|archiveurl=https://archive.today/20130415091638/http://www.hupo.org/research/psi/people.asp|archivedate=2013-04-15}}</ref> | Srivastava is an elected member of the [[American Joint Committee on Cancer]] (AJCC), responsible for developing cancer staging criteria, and serves on the AJCC Executive Committee and the All Ireland-NCI Consortium.<ref>{{cite web|url=http://www.allirelandnci.com/Results.aspx|title=All Ireland-NCI Consortium}}</ref> Srivastava is a founding member of [[HUPO]], participated in the Plasma Proteome and the Liver Proteome Projects, and supported several HUPO-supported initiatives.<ref>{{cite web|url=http://www.hupo.org/research/psi/people.asp|title=HUPO-supported initiatives|url-status=dead|archiveurl=https://archive.today/20130415091638/http://www.hupo.org/research/psi/people.asp|archivedate=2013-04-15}}</ref> | ||
==References== | ==References== | ||
| Line 38: | Line 34: | ||
5. "[http://www.hupo.org/research/psi/people.asp.]" | 5. "[http://www.hupo.org/research/psi/people.asp.]" | ||
6. "[ | 6. "[https://edrn.nci.nih.gov/.]" | ||
}} | }} | ||
Latest revision as of 10:18, 15 July 2025
Sudhir Srivastava | |
|---|---|
| Occupation | Scientist |
Sudhir Srivastava is chief of the Cancer Biomarkers Research Group of the Division of Cancer Prevention at the United States NCI.[1][2] Srivastava has held this position since 2000. He is a co-author of the Bethesda Guidelines for the diagnosis of Hereditary non-polyposis colorectal cancer (HNPCC).[1]
Srivastava is an elected member of the American Joint Committee on Cancer (AJCC), responsible for developing cancer staging criteria, and serves on the AJCC Executive Committee and the All Ireland-NCI Consortium.[3] Srivastava is a founding member of HUPO, participated in the Plasma Proteome and the Liver Proteome Projects, and supported several HUPO-supported initiatives.[4]
References[edit | edit source]
- ↑ 1.0 1.1 "Division of Cancer Prevention Staff: Sudhir Srivastava".
{{cite web}}: CS1 maint: deprecated archival service (link) - ↑ "Cancer Biomarkers Research Group". Archived from the original on 8 October 2012.
- ↑ "All Ireland-NCI Consortium".
- ↑ "HUPO-supported initiatives".
{{cite web}}: CS1 maint: deprecated archival service (link)